MyC-CaP is an epithelial-like cell line that was isolated in 2005 from the prostate of a 16-month-old, male mouse with prostate cancer. The animal was never exposed to hormone ablation. The cells have an amplified androgen receptor gene despite …

Herein, we describe a detailed protocol for the orthotopic engraftment of a murine prostate cancer cell line (Myc-CaP) into the anterior prostate of an immune competent mouse. Keywords: Orthotopic allograft, Myc-CaP, Prostate, Cancer, Metastasis, in vivo, Mouse model.

Aug 18, 2021 · Here, we adapt the Myc-CaP cell line for use as a PCa androgen dependent, immune competent bone metastases model and characterize the metastases.

Mouse prostate cancer Myc-CaP cells readily form bone tumors in FVB/NJ mice. Tumors are grossly confined to bone after intraosseous injection. Myc-CaP bone tumors have a mixed osteolytic/osteosclerotic morphology. Syngeneic Myc-CaP tumors model key aspects of prostate cancer bone metastases.

In addition, we successfully utilized a conditional reprogramming method to establish a cell line (B6MYC-CaP) that displayed tumorigenic ability in vivo. B6MYC-CaP cells expressed full-length and-rogen receptor (AR) without evidence of de novo AR splice variant expression.

Aug 9, 2022 · MYC induces several biosynthetic programmes and primary cells overexpressing MYC are highly sensitive to glutamine withdrawal suggesting that MYC-induced sensitisation to apoptosis may be due...

Dec 15, 2005 · Myc-CaP cells represent a unique reagent for dissecting discreet steps in hormone-refractory prostate cancer progression and show the general utility of using genetically engineered mouse models for establishing new prostate cancer cell lines.

Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.

Jul 19, 2021 · We found that castration resulted in increased expression of interleukin-8 (IL-8) and its probable murine homolog Cxcl15 in prostate epithelial cells.

Oct 1, 2021 · Mouse prostate cancer Myc-CaP cells readily form bone tumors in FVB/NJ mice. Tumors are grossly confined to bone after intraosseous injection. Myc-CaP bone tumors have a mixed osteolytic/osteosclerotic morphology. Syngeneic Myc-CaP tumors model key aspects of prostate cancer bone metastases.